Based on our findings, targeting the active, phosphorylated form of PLK1 in Cr-HCC may provide greater therapeutic benefit than in HBV-HCC, where PLK1Thr210 activation was minimal. This evidence concerns the gene PLK1 and hepatocellular carcinoma.